These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 21757259)

  • 1. [EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease].
    Heidenreich A; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Mottet N; Schmid HP; van der Kwast T; Wiegel T; Zattoni F
    Actas Urol Esp; 2011 Oct; 35(9):501-14. PubMed ID: 21757259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.
    Heidenreich A; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Mottet N; Schmid HP; van der Kwast T; Wiegel T; Zattoni F;
    Eur Urol; 2011 Jan; 59(1):61-71. PubMed ID: 21056534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Jan; 65(1):124-37. PubMed ID: 24207135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EAU guidelines on prostate cancer.
    Heidenreich A; Aus G; Bolla M; Joniau S; Matveev VB; Schmid HP; Zattoni F;
    Eur Urol; 2008 Jan; 53(1):68-80. PubMed ID: 17920184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EAU guidelines on prostate cancer.
    Aus G; Abbou CC; Bolla M; Heidenreich A; Schmid HP; van Poppel H; Wolff J; Zattoni F;
    Eur Urol; 2005 Oct; 48(4):546-51. PubMed ID: 16046052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [EAU guidelines on prostate cancer].
    Heidenreich A; Aus G; Bolla M; Joniau S; Matveev VB; Schmid HP; Zattoni F;
    Actas Urol Esp; 2009 Feb; 33(2):113-26. PubMed ID: 19418833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; Van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Eur Urol; 2011 Apr; 59(4):572-83. PubMed ID: 21315502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Mottet N; Bellmunt J; Bolla M; Briers E; Cumberbatch MG; De Santis M; Fossati N; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; Matveev VB; Moldovan PC; van den Bergh RCN; Van den Broeck T; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Cornford P
    Eur Urol; 2017 Apr; 71(4):618-629. PubMed ID: 27568654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Mottet N; van den Bergh RCN; Briers E; Van den Broeck T; Cumberbatch MG; De Santis M; Fanti S; Fossati N; Gandaglia G; Gillessen S; Grivas N; Grummet J; Henry AM; van der Kwast TH; Lam TB; Lardas M; Liew M; Mason MD; Moris L; Oprea-Lager DE; van der Poel HG; Rouvière O; Schoots IG; Tilki D; Wiegel T; Willemse PM; Cornford P
    Eur Urol; 2021 Feb; 79(2):243-262. PubMed ID: 33172724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Cornford P; van den Bergh RCN; Briers E; Van den Broeck T; Brunckhorst O; Darraugh J; Eberli D; De Meerleer G; De Santis M; Farolfi A; Gandaglia G; Gillessen S; Grivas N; Henry AM; Lardas M; van Leenders GJLH; Liew M; Linares Espinos E; Oldenburg J; van Oort IM; Oprea-Lager DE; Ploussard G; Roberts MJ; Rouvière O; Schoots IG; Schouten N; Smith EJ; Stranne J; Wiegel T; Willemse PM; Tilki D
    Eur Urol; 2024 Aug; 86(2):148-163. PubMed ID: 38614820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
    BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adenocarcinoma of the prostate].
    Dvorácek J
    Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
    Cornford P; van den Bergh RCN; Briers E; Van den Broeck T; Cumberbatch MG; De Santis M; Fanti S; Fossati N; Gandaglia G; Gillessen S; Grivas N; Grummet J; Henry AM; der Kwast THV; Lam TB; Lardas M; Liew M; Mason MD; Moris L; Oprea-Lager DE; der Poel HGV; Rouvière O; Schoots IG; Tilki D; Wiegel T; Willemse PM; Mottet N
    Eur Urol; 2021 Feb; 79(2):263-282. PubMed ID: 33039206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Practice guideline 'Prostate cancer: diagnosis and treatment'].
    de Reijke TM; Battermann JJ; van Moorselaar RJ; de Jong IJ; Visser AP; Burgers JS
    Ned Tijdschr Geneeskd; 2008 Aug; 152(32):1771-5. PubMed ID: 18754308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years.
    Postma R; de Vries SH; Roobol MJ; Wildhagen MF; Schröder FH; van der Kwast TH
    Cancer; 2005 Feb; 103(4):708-16. PubMed ID: 15648082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.